Triptorelin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Triptorelin

Also known as: Triptorelin pamoate, Triptorelin acetate, Triptorelin embonate, D-Trp6-LHRH, Decapeptyl, Triptodur, GnRH agonist triptorelin

Gonadotropin-releasing hormone (GnRH) agonist / Luteinizing hormone-releasing hormone (LHRH) agonist; synthetic decapeptide

Research chemicalLast updated: October 31, 2026Based on 34 peer-reviewed studies

What it is

Triptorelin is a hormone-suppressing peptide FDA-approved for central precocious puberty, prostate cancer, and breast cancer treatment. It works by initially stimulating and then shutting down the production of sex hormones from the pituitary. Prescription-only; approved for multiple indications; also used in gender medicine for puberty suppression.

The scientific side

Triptorelin is a synthetic GnRH analogue in which glycine-6 of the native GnRH molecule is substituted with D-tryptophan, increasing resistance to enzymatic breakdown and affinity for LHRH receptors. This substitution confers a superagonistic effect and a biological half-life approximately 10-fold longer than the native hormone after subcutaneous injection. Upon initial administration, triptorelin stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, causing a transient "flare-up" in testosterone or estrogen levels; with continued exposure, it triggers receptor down-regulation (decrease in receptor synthesis), resulting in sustained suppression of LH, FSH, and downstream sex steroids (PMID 22691297, PMID 16302716). In prostate cancer patients, this mechanism initially surges LH and testosterone, followed by suppression — leading to medical castration. In central precocious puberty (CPP), sustained pituitary-gonadal axis suppression halts premature pubertal development. Triptorelin also binds LHRH receptors overexpressed on certain cancer cells (e.g., triple-negative breast cancer, GnRH-receptor-positive breast cancer cells), enabling targeted drug delivery applications.

Class: Gonadotropin-releasing hormone (GnRH) agonist / Luteinizing hormone-releasing hormone (LHRH) agonist; synthetic decapeptide

Legal & regulatory status

US FDA

Approved (FDA) for central precocious puberty (Triptodur cited, PMID: 29294465); approved in association with tamoxifen or aromatase inhibitor and with fulvestrant and palbociclib in premenopausal women with hormone…

WADA

GnRH analogs including triptorelin are on the World Anti-Doping Agency (WADA) list of prohibited substances

Health Canada

Not stated in reviewed literature — requires manual verification